Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

hVIVO acquires CRS Berlin for clinical expertise

PRIVATEAug 27, 2026about 3 hours ago

Acquiring Company

hVIVO plc

Acquired Company

CRS Clinical Research Services Berlin GmbH

LondonGermanyBiotechnologyHealth CareBiotechnologyHealth CarePharmaceutical

Description

hVIVO plc has acquired CRS Clinical Research Services Berlin GmbH, enhancing its presence in dermatology and women's health. This acquisition is expected to improve hVIVO's revenue and EBITDA in FY26 with a contracted orderbook of €10 million. The move aligns with hVIVO's strategy to build a global clinical network. Upfront consideration for the acquisition is €0.025 million, with additional earnout payments based on future revenue.

Company Information

Company

hVIVO plc

Location

London, England, United Kingdom

About

hVIVO plc is a leading early-stage Contract Research Organisation (CRO) specializing in human challenge clinical trials. The company is known for its expertise in in-patient Phase I and Phase II trials and aims to diversify its service capabilities through strategic mergers and acquisitions.

Don't miss hVIVO plc's next move

Get an email the moment hVIVO plc makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for hVIVO plc's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired CRS Clinical Research Services Berlin GmbH?

CRS Clinical Research Services Berlin GmbH was acquired by hVIVO plc, based in London. The deal was reported on August 27, 2026. hVIVO plc is a leading early-stage Contract Research Organisation (CRO) specializing in human challenge clinical trials. hVIVO plc is privately held and operates in Biotechnology.

When did hVIVO plc acquire CRS Clinical Research Services Berlin GmbH?

hVIVO plc's acquisition of CRS Clinical Research Services Berlin GmbH was reported on August 27, 2026. hVIVO plc has acquired CRS Clinical Research Services Berlin GmbH, enhancing its presence in dermatology and women's health. This acquisition is expected to improve hVIVO's revenue and EBITDA in FY26 with a contracted orderbook of €10 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does CRS Clinical Research Services Berlin GmbH do?

CRS Berlin is a specialist clinical research unit focused on Phase I/II clinical studies. It serves pharmaceutical and biotechnology clients, particularly in dermatology and women's health. It is privately held, operating in Biotechnology, and is based in Germany.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.